7/8/2013 Cowen and Company Boost Price Target Avanir Pharmaceuticals Inc. (AVNR) $12.00
7/8/2013 Summer Street Boost Price Target Avanir Pharmaceuticals Inc. (AVNR) Buy $16.00
Mizuho Securities analyst Mario Corso defended Avanir Pharmaceuticals (NASDAQ: AVNR) in response to a negative report by Gravity Research yesterday. In Corso's view, concerns raised by Gravity are "off the mark."
The report raised concerns about off label marketing and patents.
In Corso's view focus on Nuedexta IP and marketing are overblown. He continues to see Avanir having robust patents and high change of winning generic lawsuit.
Mizuho Securities has a Buy rating on Avanir Pharmaceuticals with a price target of $11.00